Genkyotex, a Switzerland-based chronic disease treatment company, has raised CHF20m ($21m) in its series D round from a consortium including Swiss Federal Institute of Technology in Zürich-backed VI Partners.
VI partners was joined in investing for the first time in the round by Switzerland-based venture capital companies Neomed Management and BioMedInvest.
The round also saw reinvestment from venture capital companies Edmond de Rothschild Venture Capital and Swiss academic research commercialisation unit Eclosion2, and Luxembourg-based venture capital company Vesalius Biocapital Partners.
…
